Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract 5782).
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care am...
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes a special panel discussion on ways to eliminate cancer he...
Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with...
Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by ge...
Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint b...